Synta Pharmaceuticals (SNTA Quote): Melanoma has been a drug development graveyard, but Synta's experimental drug elesclomol has a shot at success. There was additional and positive data presented here from the company's randomized phase II study. It wasn't earth shattering but it does explain and support the dosing and design of the ongoing phase III study, which should have data in early 2009.
Anything melanoma-related is high risk, but Synta conducted a randomized, controlled phase II study that was positive, so on that basis alone, elesclomol deserves at least a look. Position: None- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,390.11 | 1,103.25 | 2,189.61 | 34.48 |
Oil *
76.70
|
|
UP
1.21
|
DOWN
2.73
|
DOWN
4.74
|
DOWN
0.35
|
10 Yr
3.45%
SPDR Gold
113.11
|
|
+0.01%
|
-0.25%
|
-0.22%
|
-1.00%
|
Data delayed 20 minutes |
